Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 12/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10776429 | 0.89 | CNR2 (0.52) | SIGMAR1CNR2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL17811537 | 0.86 | SIGMAR1 (0.46) | SIGMAR1HTR2AHRH1ALDH1A1MAPK1 | |
| SCHEMBL14283608 | 0.80 | CNR2 (0.52) | SIGMAR1CNR2HTR2AHRH1ALDH1A1 | |
| SCHEMBL14283583 | 0.80 | CNR2 (0.52) | SIGMAR1CNR2HTR2AHRH1ALDH1A1 | |
| SCHEMBL12145187 | 0.78 | ALDH1A1 (0.49) | SIGMAR1CNR2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL17811540 | 0.78 | SIGMAR1 (0.39) | SIGMAR1HTR2AHRH1ALDH1A1MAPK1 | |
| SCHEMBL14283586 | 0.78 | ALDH1A1 (0.52) | SIGMAR1CNR2ALDH1A1TSHRCYP3A4 | |
| SCHEMBL27702362 | 0.77 | SIGMAR1 (0.53) | SIGMAR1CNR2HTR2AHRH1ALDH1A1 | |
| SCHEMBL10951456 | 0.77 | CYP2C19 (0.53) | SIGMAR1CNR2HTR2AHRH1TSHR | |
| SCHEMBL19754081 | 0.77 | SIGMAR1 (0.42) | SIGMAR1HTR2AHRH1TSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | TRINSEO EUROPE GMBH (CH) | 2018-06-26 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-20160159956-A1 | Polymerisation Initiators | TRINSEO EUROPE GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005869-B2 | Polymerisation initiators | ELOVL5, ELOVL3, ELOVL1 | SIGMAR1 2592/4885CNR2 1455/4885HTR2A 3689/4885 |
| US-20160159956-A1 | Polymerisation Initiators | ELOVL5, ELOVL3, ELOVL1 | SIGMAR1 2592/4885CNR2 1455/4885HTR2A 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.